JY
ACHL

Jeff Yass’s Achilles Therapeutics ACHL Stock Holding History

Jeff Yass’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,434
Closed -$12.7K – 13494
2024
Q3 		$12.7K Buy
+12,434
New +$9.96K ﹤0.01% 11694
2023
Q2 		– Sell
-13,900
Closed -$13.3K – 13362
2023
Q1 		$13.3K Hold
13,900
– – ﹤0.01% 12153
2022
Q4 		$12.5K Buy
+13,900
New +$23.4K ﹤0.01% 11893

Other funds holding ACHL

SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Jeff Yass's ACHL Position: Q4 2024 in Review

Jeff Yass sold out of Achilles Therapeutics (ACHL) in Q4 2024, closing a stake of 12,434 shares — an estimated $12.7K sold.

Jeff Yass first reported a position in ACHL in Q4 2022 and held it in 3 quarters. The position peaked at $13.3K in Q1 2023. 21 funds tracked by Wall St. Rank hold ACHL as of Q4 2024.

  • Jeff Yass reported no remaining Achilles Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Jeff Yass sold 12,434 Achilles Therapeutics shares in Q4 2024, an estimated $12.7K.
  • Jeff Yass first reported a position in Achilles Therapeutics in Q4 2022 and held it in 3 quarters.
  • Jeff Yass's Achilles Therapeutics position peaked at $13.3K in Q1 2023.
  • 21 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q4 2024.

Based on Susquehanna International Group's 13F filing for Q4 2024, filed 14 Feb 2025.